The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2018 | Pembrolizumab trial shows promising responses in cutaneous lymphoma
Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, speaks at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland. Dr Khodadoust discusses the CITN-10 trial (NCT02243579), which investigated the use of pembrolizumab in relapsed/refractory mycosis fungoides or Sézary syndrome. He highlights the patient response rates and a uniquesideeffect that was observed in the Sézary population.
